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Natural killer cells are a unique type of lymphocytes with cytotoxic capacity, and play impor-
tant  roles against tumors and infections. Recently, natural killer cells have been increasingly
valued in their effects in hepatitis B virus infection. Since hepatitis B virus is not cytopathic,
the  subsequent antiviral immune responses of the host are responsible for sustaining the
liver  injury, which may result in cirrhosis and even hepatocellular carcinoma. Many stud-
ies  have conﬁrmed that natural killer cells participate in anti-hepatitis B virus responses
both  in the early phase after infection and in the chronic phase via cytolysis, degranulation,
and cytokine secretion. However, natural killer cells play dichotomic roles: they exert antivi-
ral  and immunoregulatory functions whilst contribute to the pathogenesis of liver injury.
Here, we review the roles of natural killer cells in hepatitis B virus infection, introducingnovel therapeutic strategies for controlling hepatitis B virus infection via the modulation of
natural killer cells.
© 2015 Elsevier Editora Ltda. All rights reserved.ntroduction
epatitis B virus (HBV) infection is one of the most common
hronic viral infections in humans. HBV is not cytopathic, i.e.
hen cellular immune responses are deﬁcient or pharmaco-
ogically suppressed, HBV can replicate at high levels in vivo
ithout detectable pathological consequences.1,2 It has been
hown that liver injury is in fact due to the antiviral immune
esponse of the host. In chronic HBV infection, prolonged
rogress may cause persistent liver inﬂammation, eventually
esulting in cirrhosis and hepatocellular carcinoma (HCC).3
It is well known that virus-speciﬁc CD8+ cytotoxic T lym-
hocytes and CD4+ T-helper cells play effective and regulatory
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immunity have triggered extensive debates. Innate immunity
is considered to compose the ﬁrst-line host defense against
pathogens, including sensing danger signals, controlling viral
replication and dissemination very early after infection, as
well as for timely orchestration of virus-speciﬁc adaptive
responses.5 However, it has been reported that HBV does not
modulate host cellular gene transcription, and would there-
fore induce neither innate antiviral response in hepatocytes
nor intrahepatic innate immune responses.6 Furthermore,authorship.
a portion of chronically infected patients undergo a long-
lasting immune tolerance phase that is characterized by a
lack of clinical symptoms and high HBV load.7 Hence, the
innate immunity is deemed to account for the “absence” of
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anti-HBV response. Nevertheless, some ﬁndings are inconsis-
tent with these conclusions, suggesting an active role of innate
immunity in HBV clearance. Natural killer (NK) cells are an
essential part of the innate immune system, and participate
in the antiviral responses despite the dichotomic character-
istics they display.8 Here, we  will review the recent studies
regarding altered NK cells phenotypes and functions in HBV
infection.
General  features  of  NK  cells
Human NK cells are generally deﬁned as a group of lympho-
cytes that express CD56 but lack the T cell receptor (TCR)–CD3
complex. They represent about 15% of all peripheral blood
lymphocytes and this proportion can rise to more  than 30%
in the liver.9 NK cells exert their effects mainly through
the recognition and killing of target cells and the secretion
of cytokines such as interferon- (IFN-) and tumor necro-
sis factor- (TNF-),  which can modulate antiviral immune
responses. By producing antiviral cytokines and chemokines,
NK cells also play an important role in bridging the innate
and adaptive immune responses.10 NK cells can be further
divided into two subsets, the CD56bright and the CD56dim
subsets, according to the cell membrane density of CD56.
CD56dim NK cells, expressing high levels of the low-afﬁnity
Fc-receptor CD16 and the killer immunoglobulin-like recep-
tor (KIR), represents about 90% of all blood NK cells, whilst
CD56bright NK cells constitute less than 10% of all blood
NK cells and do not express CD16 and KIR.11 Referring to
functions, CD56dim NK cells efﬁciently kill target cells by degra-
nulation but secrete low levels of cytokines; on the other hand,
CD56bright NK cells produce a large amount of cytokines upon
stimulation but are less cytotoxic. However, CD56bright cells
exhibit similar or enhanced cytotoxicity against target cells
after prolonged activation compared with CD56dim cells.12 In
addition, CD56bright NK cells constitutively express the high-
and intermediate-afﬁnity interleukin-2 receptors (IL-2R) and
expand in vitro and in vivo in response to low doses of IL-2.9,13,14
On the contrary, resting CD56dim NK cells only express the
intermediate-afﬁnity IL-2R and proliferate weakly in response
to high doses of IL-2 in vitro, even after induction of the high-
afﬁnity IL-2R.9,11,13
NK cells express an array of receptors including inhibitory
and activating receptors, inducing negative and positive sig-
nals when combined with their ligands, which can determine
whether or not NK cells become activated, enabling them
to detect infected or neoplastic cells while sparing normal
cells.15 MHC  class I molecules, encoded by highly conserved
genes inherited independently and expressed by most nor-
mal  cells, are natural ligands for NK cell inhibitory receptors.
Thus, the strength of the activating signals on encountering
normal cells is dampened by inhibitory signals, and NK cells
are left quiescent. However, MHC  class I molecules are often
down-regulated on cancerous or virus-infected cells, deliver-
ing insufﬁcient inhibitory signals, thus activating NK cells.
This is known as the “missing-self” mechanism of NK cell
activation. In another condition, NK cells are selectively acti-
vated by ‘stressed’ cells, which express upregulated activating
ligands for NK cells and thereby overcome the inhibitory
signaling delivered by MHC  class I molecules. This is known 1 5;1  9(4):417–425
as the “stress-induced self” triggering of NK cell activation16,17
(Fig. 1). In both conditions, NK cell activation leads to degranu-
lation and/or cytokine secretion. In addition, NK  cells can be
activated upon stimulation by IL-12, IL-15, IL-18 and IFN-/.14
NK  cells  in  the  early  immune  responses  to  HBV
infection
Innate immunity is the ﬁrst barrier against infection and neo-
plastic growth, and is distinguished by the rapid participation
in the early response to antigens without presensitization.
NK cells, as an important element of the innate immunity,
display at least three effector functions that contribute to
infection control: they can directly kill infected cells by releas-
ing cytolytic granules, induce apoptosis of target cells through
crosslinking death receptors and ligands, and produce a vari-
ety of immunomodulative cytokines (Fig. 2). Studies have
conﬁrmed that NK cells take part in the antiviral responses
to certain RNA viruses (e.g. HIV, HCV) and DNA viruses (e.g.
CMV).18–20 However, HBV is currently considered as a “stealth”
virus and its infection is characterized by a lack of obvious
symptoms and liver damage that even lasts for several years.
On this account, patients at the very early stage of infection
are almost unrecognizable. On the other hand, only chim-
panzee and tupaia can be infected naturally by HBV, providing
insufﬁcient animal models for its study. Although woodchuck
infected with the woodchuck hepatitis virus (WHV) offers a
favorable model,21 whether it is an entirely representative of
the human setting is yet to be discussed. Mouse models of per-
sistent HBV infections that are analogous to those of human
chronic HBV infections have been established,22,23 but with
the same problems as with the woodchuck model. To date,
taking into consideration these factors, our cognition of the
anti-HBV innate immune responses at the earliest presymp-
tomatic stages is still limited.
Some studies suggest that NK cells and even innate immu-
nity do not signiﬁcantly contribute to the initial control of
HBV infection. Studies in chimpanzees and woodchucks have
shown that HBV does not induce signiﬁcant changes in intra-
hepatic gene expression during entry and reproduction in the
liver, and the viral load does not decrease until the onset of the
adaptive immune response, several weeks later.24,25 With the
development of infection, the clearance of HBV-infected hepa-
tocytes by adaptive immunity correlates with elevated levels
of IFN- and TNF- in the liver,2 which could be produced by
activated NK cells. However, follow-up experiments indicate
that rather than NK cells, CD8+ cells, which are also sources
of IFN- and TNF-, are the main effector cells responsible for
viral clearance.26
However, some other experiments showed contradic-
tory results. NK cells express mRNAs coding for toll-like
receptors (TLR), TLR1 to TLR9, which recognize certain non-
self molecules and initiate immune responses.27 In vitro,
HBV-plasmid DNA promotes NK cell activation including
cytotoxicity and IFN- production in the liver through
28TLR/IFN--mediated signaling pathways. In a study carried
out in a high-titer HBV replication mouse model, NK cells
were required to eliminate HBV infection, presumably through
the induction of HBV-speciﬁc CD8+ T cell response.28 Early
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Fig. 1 – Recognition of healthy and stressed cells by NK cells. (a) MHC  I molecules are expressed by most normal cells, which
transmit inhibitory signals. The strength of inhibitory signals overcomes activating signals, and NK cells are left
unactivated. (b) MHC  I molecules are often down-regulated on stressed cells, offering insufﬁcient inhibitory signals, thus
activating NK cells. This is the “missing-self” mechanism of NK cell activation. (c) Some stressed cells up-regulate activating
ligands rather than down-regulate MHC  I molecules, which deliver overwhelming activating signals and activate the NK
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mells. This is the “stress-induced self” mechanism of NK cel
fter infection with high titers of WHV,  NK cells were acti-
ated and virus load was reduced signiﬁcantly, suggesting
hat the innate response is activated in the liver soon after
xposure to a certain dose of WHV.29 Owing to the delayed
ppearance of symptoms or the totally asymptomatic nature
f HBV infection, studies of the early immune events in HBV-
nfected people are rare. A study of two blood donors who
ere identiﬁed by accident to have seroconverted with the
ppearance of hepatitis B surface antigen (HBsAg) and sub-
equent rise of HBV viremia without alanine aminotransferse
ALT) elevation, have shown that NK cells are able to mount
n early and efﬁcient response to HBV, and that the innate
mmune system is able to recognize HBV from the beginning of
he infection, which probably contributes to the timely induc-
ion of adaptive responses.30 In acute hepatitis B, activation
eceptor-expressing NK cells are preferentially enriched, while
he inhibitory receptor-expressing NK cells are reduced.31
oreover, according to two independent studies, NK cells
isplayed increased or decreased cytolytic activity and IFN-
31,32roduction. These results reveal that NK cells participate
n the early-stage response after HBV infection.
However, most of these studies were carried out in animal
odels, which may not fully represent the reality in humans.vation.
On the other hand, data from human beings are insufﬁcient.
Hence, the role of NK cells in the early phase of HBV infection
is still to be demonstrated in humans.
Contribution  of  NK  cells  to  HBV-induced  liver
injury
In HBV infection, NK cells always play contradictory roles, as
they exert antiviral and immunoregulatory functions whilst
contribute to the pathogenesis of liver injury. The apoptosis
of HBV-infected hepatocytes is in favor of self-protection as it
helps to viral clearance. But in the case of sustained infection,
the continuous injury to the liver is the precondition for liver
ﬁbrosis and HCC. In the immune-activated stage of chronic
hepatitis B (CHB), NK cells skew toward a cytolytic activity,
which correlates positively with the severity of liver damage.33
Enhanced cytolytic activity of NK cells can be partly attributed
to altered levels of certain cytokines33 and to the recognition
34between NKG2D and its ligands.
Other than cytotoxic effectors-mediated liver damage,
apoptotic signal transmission is also an important factor
causing hepatocyte death. In healthy livers, NK cells express
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Fig. 2 – NK cells mediate their functions through at least three mechanisms: releasing perforin/granzyme for cytolysis,
osslidelivering intercellular signaling through receptor–ligand cr
little or no TNF-related apoptosis-inducing ligand (TRAIL) on
their surface35 and hepatocytes express minimal TRAIL death-
inducing receptors.36 However, in patients with HBV and
liver inﬂammation, TRAIL-expressing NK cells are enriched
in the liver and the hepatocytes express upregulated lev-
els of the TRAIL death-inducing receptor, indicating that NK
cells may contribute to liver inﬂammation by TRAIL-mediated
death of hepatocytes.37 Besides, after being activated, NK
cells may induce massive HBV-infected hepatocyte degen-
eration through the Fas/Fas ligand interaction,38 and are
even involved in the disease progression of HBV-related
acute-on-chronic liver failure (ACLF).39 Intrahepatic PD-1/PD-
L1 up-regulation is closely associated with the viral load and
inﬂammatory responses, which decreases simultaneously
with inﬂammation remission, implying that the PD-1/PD-L1
system participates in liver injury.40,41 Although NK cell dys-
function is reported to correlate with PD-1 up-regulation,42
direct evidences are lacking to certify that PD-1 alters NK cell
function in HBV infection.
NK  cells  in  chronic  HBV  infectionThe controversial role of NK cells in the acute phase of HBV
infection has been underlined above. In chronic infection, NK
cells display varying changes in proportion, phenotype and/ornking, and secreting cytokines.
function, which differ between studies. The defects in NK cells
are reﬂected in many  aspects: (1) the percentages of hepatic
and peripheral NK cells are reduced in immune-activated
CHB patients, with or without changes in their subsets33,43,44;
(2) altered expression of activating or inhibitory receptors
on NK cells33,43–46; (3) up-regulation of some molecules with
inhibitory effects such as T cell immunoglobulin and mucin
domain containing molecule-3 (Tim-3);47 (4) maintained or
even enhanced cytolytic activity, which is correlated to the
severity of liver injury33,43,46; and (5) impaired capacity to
produce cytokines such as IFN- and TNF-.43,44,46,47 Viral
load reduction through anti-viral therapy partly restores NK
cells numbers, cytokine production and inhibitory recep-
tor expression.43,45,48,49 Although these studies are mostly
consistent, there are discordances in some details such as
the changes in the expression of some receptors33,43–46 and
changes in cytolytic activity. The reasons for these differences
are not clear yet, but may be ascribed to ethnic variations,
sample size, disease process and severity. Despite inconsistent
conclusions between studies, NK cells display intact or even
increased cytotoxicity but impaired anti-viral cytokines secre-
tion during chronic HBV infection, and these changes may be
partly rectiﬁed after viral load reduction.
The factors contributing to NK cell dysfunction were
demonstrated by many  studies. NK cells express mRNAs  for all
known TLRs. Through these ligands, NK cells may be directly
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teceptor expression. Disordered NK cells subsequently medi
timulated to induce the production of IFN-.27 A recent study
evealed that NK cells can be activated by HBV-based DNA
lasmids in a TLR-dependent manner, displaying enhanced
K cell effector functions including cellular cytotoxicity and
FN- production.26 However, in the persistent HBV infection
hase, NK cells suffer functional disorders that can be restored
ith viral replication suppression. It can be deduced that dur-
ng long-lasting virus replication, NK cells are inﬂuenced by
athological circumstances induced by the HBV infection.
NK cells interact with some other immune cells through
eceptor–ligand combination and/or regional cytokine secre-
ion. Dendritic cells (DCs) are the most important antigen-
resenting cells, and are divided into myeloid dendritic cells
mDC) and plasmacytoid dendritic cell (pDC). DCs bridge
he innate and adaptive immunities, and consequently play
ivotal roles in eliminating external antigens. During HBV
nfection, both mDCs and pDCs display functional defects,50–52
hich inﬂuence the cross talk with NK cells, making inefﬁ-
ient the NK cells activation. mDCs are substantially impaired
n their ability to activate NK cells via decreased mDC-derived
ytokine secretion, which in turn fail to secrete adequate
mounts of IFN-.52 pDCs are poor NK activators, potentially
hrough an OX40L/IFN--dependent pathway53,54 (Fig. 3).D8+ T cells death.
Besides DCs, intrahepatic Kupffer cells also participate in
the anti-HBV immune response, partly through interfering
with the NK cells. Kupffer cells are the main source of the
immune-suppressive cytokine interleukin-10 (IL-10), which
maintains the humoral immune tolerance during persistent
HBV infection55 (Fig. 3). IL-10 acts as an inhibitory cytokine
blunting NK activation, which restrains IFN- secretion.56
However, another study demonstrated that IL-10 had a sig-
niﬁcant effect on NK cytotoxicity rather than on IFN- or
TNF- production or NK cell activatory receptor expression.57
Blocking the IL-10 pathway may correct defective capacity of
NK cells to produce IFN-.58 Furthermore, plasma levels of
transforming growth factor-1 (TGF-1) is also elevated during
HBV infection,59 which may impair NK cell-mediated cyto-
toxic capacity and IFN- production by down-regulating the
expression of the activating receptors NKG2D and 2B4. More-
over, their intracellular adaptor proteins, respectively DAP10
and SAP, are also decreased.60
Since the immune system is a reticular and syntrophic
entirety, NK cell dysfunction also inﬂuences the function of
the other parts of the system, especially effector T cells.
CD8+ T cells are the main effector cells responsible for
viral clearance and disease pathogenesis during acute HBV
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infection.25 However, in the chronic infection stage, they are
markedly diminished in number and exhaustive in functions
in patients who  failed to control virus replication.61,62 The
decrease in CD8+ effector T cells can be partly attributed to
NK cells, because NK cells cannot only mediate CD8+ T cells
death through up-regulation of TRAIL receptors,63 but also
limit CD8+ T cells immunity by NKG2D- and 2B4-dependent
perforin-mediated lysis64,65 (Fig. 3).
Unfortunately, the restoration of HBV-speciﬁc CD8+ T cells
is difﬁcult to achieve. Even if a favorable virological response is
obtained after anti-viral treatment, HBV-speciﬁc CD8+ T cells
remain at low levels and express an exhausted phenotype.66,67
This “permanent signature” may result from chronic exposure
to HBV-related antigens, which in turn changes the differen-
tiation program of CD8+ T cells. Unlike what is observed in
HBV infection, type I interferon can protect anti-viral CD8+ T
cells from elimination by NK cell-mediated perforin expres-
sion in lymphocytic choriomeningitis virus infection.68 These
diverse mechanisms may partly explain why CHB is clini-
cally difﬁcult to manage, with an unsatisfying response rate
to IFN treatment. Furthermore, although not yet observed in
HBV infection, NK cells may prevent activated CD4+T cells
from being killed by the interaction between NKG2A and its
ligand.69
NK cells may not be as important as DCs in bridging the
innate and adaptive immunities, but their roles are unique,
and correlational studies are attracting more  and more  atten-
tion in HBV infection.
NK  cells  as  potential  targets  for  immunotherapy
In the clinical setting, currently available antiviral treatment
for CHB infection can be divided into two classes of ther-
apeutic agents: nucleos(t)ide analogs (NAs) and IFN-. NAs
include nucleoside (lamivudine, telbivudine and entecavir) or
nucleotide (adefovir and tenofovir) analogs. The major advan-
tages of NAs are good tolerance and potent antiviral activity
associated with high rates of on-treatment response to ther-
apy. The advantages of IFN include a ﬁnite course of treatment,
absence of drug resistance, and an opportunity to achieve a
durable response to therapy. Obviously, the advantages of one
agent are the disadvantages of the other. Besides, the two
agents have been conﬁrmed to contribute little to the restora-
tion of HBV-speciﬁc CD8+ T cells. Since current therapies are
far from sufﬁcient from economical and effectiveness points
of view, novel therapeutic strategies are in great need. It is
unclear why individuals respond differently to IFN,70 but it is
supposed to be due, at least in part, to NK cell characteris-
tics including cell numbers, receptor expression and function
alteration.67,71 Similar results were also obtained with the use
of NAs,43,45 indicating that the modulation of NK cell function
may help to suppress HBV replication. Aberrant DNA methyla-
tion is an early and ubiquitous event during HCC development,
and can be detected even in precancerous liver tissues such
as chronic hepatitis, liver cirrhosis, or dysplastic nodules.72A recent study conﬁrmed that this process was closely asso-
ciated with NK cell activity.73 Hence, regulation of NK cell
function is a potential way to treat CHB and to prevent the
occurrence of cirrhosis and HCC. 1 5;1  9(4):417–425
It has been discussed above that NK cell functional alter-
ations include at least three aspects: decreased cytokine
secretion, increased cytotoxicity and apoptosis-mediating
capacity (Fig. 3). Therefore, we should turn to increasing anti-
viral cytokine production and protect other cells from being
killed, targeting on the interaction between NK cells’ recep-
tors to their ligands and cytokines in the microenvironment.
As the immune system is a complex entity, the inﬂuence on
every part of this system should be considered to formulate
new strategies in order to avoid immune overreaction.
Strategies based on the regulation of NK cell function to
treat CHB were only carried out in animal experiments so far.
NK cells may achieve enhanced anti-viral viability or allevi-
ated hepatocyte lysis by blockade of some of their activating
or inhibitory receptors and ligand interactions.45,74 Increased
expression of PD-1 in the liver results in immune disorder,
which is to the disadvantage of HBV clearance. PD-1/PD-L1
blockade could reverse immune dysfunction by augmenting
IFN- secretion and accelerating HBV elimination in vivo.75
IL-10 and TGF-1 have been shown to restrain NK cells func-
tion, and blockade of IL-10 and/or TGF-1 restored the capacity
of NK cells to produce IFN-, thereby enhancing their non-
cytolytic antiviral capacity.58,60 The contribution of IFN- and
TNF- in HBV clearance is undisputed, especially in the acute
phase of infection.2 However, in the immunotolerant and
immunoreactive phases, elevated levels of IFN- and TNF-
are not enough to help eliminating the virus, but allows sus-
taining the liver injury.76
Concluding  remarks
The reason why HBV infection is difﬁcult to manage in the
clinical setting is because of the properties of the virus itself,
but also of the immune responses of the hosts. As discussed
above, the role of NK cells in HBV infection is still controversial:
whether NK cells is involved in the early phase of HBV infec-
tion, and what alternations have been occurred to NK cells
during chronic infection are not known yet. Whereas, it cannot
be denied that the persistence of HBV infection and ongoing
liver injury could be partly due to the dysfunction of NK cells
and subsequent mediation of disorders of the immune system
and death of hepatocytes. On account of our limited knowl-
edge, new immunotherapies basing on NK cells are only in
the infancy stage. A new subset of human NK cells, denom-
inated as NK-22 cells, was recently discovered.77 They locate
in mucosa-associated lymphoid tissues, and are hard-wired to
secrete IL-22, which provide protection to hepatocytes78,79 and
promote proliferation of liver stem/progenitor cells,80 provid-
ing a novel therapeutic candidate for chronic HBV infection.
In summary, on the basis of existing achievements, more
researches are still needed to deﬁne the exact roles of NK cells
in HBV infection. New strategies should be aiming on melio-
rating the function of NK cells, inhibiting viral replication,
alleviating liver injury and avoiding cirrhosis and HCC.Conﬂicts  of  interest
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